COGT Stock Soars on Phase III Systemic Mastocytosis Study Success

Key Takeaways COGT soared after its SUMMIT study met all endpoints in non-advanced systemic mastocytosis. Bezuclastinib showed strong symptom reduction and biomarker response versus placebo. The drug was well-tolerated, and an FDA submission is targeted for the end of 2025.Shares of Cogent Biosciences (COGT) soared 23.4% on Monday after the company reported positive top-line data from a late-stage study of its investigational candidate, bezuclastinib, for treating non-advanced systemic mastocytosis (SM) p ...